International Scholarly Research Notices

Review Article

Brain Metastases from Endometrial Carcinoma

Table 1

Patients with brain metastases from endometrial carcinoma documented in the literature.
Author (year) study period (Ref.)No. of patients BM/ECAge at BMStage (FIGO) of ECGrade of ECHist of ECPrimary therapy for ECAdj. therapy for ECInterval EC to BM (mon.)Other MTSNo. of BMSite of BMTherapy for BMSurvival after BM (mon.)
Salibi and Beltaos (1972) [25]163NANAACHSONR6NoSingleSupraSAW 18
Nakano and Schoene (1975) [19]177NANACCHSORT26YesSingleSupraS + RTD 4
Turner and Graf (1982) [26]183NAG3ACHSONRNANASingleSupraSD 1
Aalders et al. (1984) 1960–1976 [24]11/3,39311 NA11 NA11 NA11 NA11 NA11 NA11 NA8 No11 NA11 NA11 NA11 NA
(0.3%)3 Yes
Ritchie et al. (1985) [27]161IIIcNAACHSORTNAYesMul.SupraNAD 4
Savage et al. (1987) [28]170IG1ACHSORT0YesSingleSupraRTD 14
Sawada et al. (1990) [29]143IIIcG3ACHSOLRT2NoSingleSupraS + RTAW 84
Brezinka et al. (1990) [21]159IcG2ACHSONo2YesSingleSupraSD 1
Kottke-Marchant (1991) 1980–1988 [30]359IIIcG3CCHSOC− 3YesSingleSupraS + RTD 37
43IIIaG3ACHSONo0NoMult.BothSD 1
46IIIaG3ACHSOC−2.5 NoSingleSupraS + RTAW 9
De Porre and Tjokrowardojo (1992) 1965–1988 [31]11/2,2936711 NA11G31ASHSOLRT81 NoSingleSupraSD 14
(0.48%)10 NA10 NA10 NA10 NA10 NA 10 NA 10 NA10 NA10 NA
Thomas and Lambert (1992) [32]151INAACHSORT24NoSingleSupraS + RTAW84
Wronski et al. (1993) [33]270NANAACHSO R T + C 22YesMult.InfraS + RTD 5.5
60NANAACHSORT88YesMult.BothRTD 2
Ruelle et al. (1994) [34]264NAG3ACHSO R T + C 14YesSingleInfraS + RTD 9
63I G3 AC HSORT−0.25NoSingleSupraS + RTAD 24
De Witte et al. (1996) [35]2670NAACHSONo24NoSingleSupraS + RTD 60
40IIIc G3ASHSOLC-UK NoSingleSupraS + RTNA
Cormio et al. (1996) 1982–1994 [36]10/1,069
(0.9%)		59 (47–71)3 Ib 2 Ic6 G38 AC5 HSO8 RT 2 C26 (3–81)4 yes6 Single7 Supra1 S1 (1–83)
4 NA1 AS4 HSOL 6 no4 mult.2 Both2 S + RT
2 IIIa1 CC1 NA1 Infra1 RT 6 Steroids
1 IIIc
2 IV
Salvati et al. (1998) [37]248IaG3ACHSORT10NoSingleSupra S + R T + C D 20
54IaG3ACHSORT26 NoSingleSupra S + R T + C D 74
Martínez-Mañas et al. (1998) [38]176IIbNRACHSORT18NoSingleNASD 8
Ogawa et al. (1999) [39]243IIbG2ACHSOLRT36YesMult.SupraRTD 5
64IIbG3ACHSOLRT18YesMult.BothRTD 3
Crispino et al. (2000) [40]157IcG3NAHSOLRT12NoSingleInfraS + RTD 3
Mahmoud-Ahmed et al. (2001) 1985–1999 [41]10a51 (48–80)1 IIa10 NA7 AC2 HSOL2 RT8 (0.25–70)7 yes3 Single8 Supra5 RT3.25
1 IIIa3AS4HSO 4 R T + C 3 no 7 Mult. 1 Both2 S(0.25–15.5)
2 IIIb 4 R T + C 4 No2-UK1 Infra3 S + RT
2 IIIc
4 IV
Petru et al. (2001) [42]259IVaG3ACHSOC-UKNoSingleSupraSRSAW 171
60IIIc G3SCHSOC -UKNoSingleInfraSRSD 15
Sewak et al. (2002) [43]163IbG3ACHSOLRT48+YesSingleInfraS + RTD 6
Shiohara et al. (2003) [44]148IIIaG3ASHSOLNo0NoSingleSupraS + SRS + CAW 38
Elliot et al. (2004) [45]151IIbG3ACHSOLRT2NoSingleSupraS + RT + CAW 30
Gien et al. (2004) 1991–2003 [46]8/1,295
(0.6%)		67.52IIb3 G24 AC3 HSO5 RT8.5 (0–40)6 yes4 Single4 Supra6 RT3.5
(48–82)4IIIc5 G32SC3HSOL2 C2 no 4 Multi. 2 Both1 C + RT(0.25−7+)
2IVb1CC1 RT1 NA2 Infra1 Steroids
1AS1 R + C
Salvati et al. (2004) [47]262IaG2ACHSORT48NoSingleSupraS + RTAW 9
51IIIcG3ACHSORT + C−0.5YesSingleSupraS + RT + CD 34
Lee et al. (2006) [48]154IbG3ACHSOLRT108NoMult.SupraRTD 0.25
Llaneza-Coto et al. (2006) [49]143IIaG3ACNoNo0NoSingleSupraSD 1
Orrù et al. (2007) 1999–2005 [50]3b61IIIcG3ACHSOC + RT17NoMult.SupraS + RTAW 64
60IIIaG3 ACHSONo6 NoSingleSupraRTD 4
49IIIbG3ACHSORT10 NoSingleSupraS + RTAW 16
Sohaib et al. (2007) [16]1/86c (1.16)NANANAACHSONANANoSingleNANANA
Chura et al. (2007) 1995–2006 [51]20/2,063
(0.97%)		64 (49–78)1 Ia3 G111 AC14 HSOL5 RT11.5 (0.6–73.6)168 SingleNA7 RT2 (0.1–39.2)
2 Ib6 G23 CS2 HSO7CYes12 Mult.4 RT + C
4 IIIa11 G32 AS4 No2 RT + C4 No1 S + RT
4 IIIc1 SC6 No1 RT + SRS
9 IVb3 UD3S + RT + C
4 No
Ramirez et al. (2008) [52]161IIbG3ACHSORT12NoMult.InfraRTD 17
Monaco et al. (2008) [53]660.46 NA6 NA6 NA6 NA6 NA6 NA6 NA6 NA6 NA6 SRS5 (0.2–25)
Al-Mujaini et al. (2008) [54]169NANAACHSORT84YesMult.SupraNANA
Forster et al. (2011) [55]158INAACHSORT108YesMult.SupraOlaparibdD18
Total1155 (0.1–171)
AC: adenocarcinoma; Adj: adjuvant; AD: alive with disease; AS: adenosquamous carcinoma; AW: alive and well; BM: brain metastases; C: chemotherapy; CC: clear-cell carcinoma; CS: carcinosarcoma; D: dead of disease; EC: endometrial carcinoma; Hist: histology; Infra: infratentorial (cerebellum); HSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy; HSOL: HSO and lymph node dissection; mon: months; MTS: metastases; Mult: multiple; NA: not available; S: surgery (craniotomy); SC: serous carcinoma; SRS: stereotactic radiosurgery; Supra: supratentorial (cerebrum); UD: undifferentiated, -UK: brain metastases detected at unknown time before the diagnosis of endometrial carcinoma.
a Endometrial carcinoma was the source of brain metastases in 10 (0.7%) of 1,391 patients with brain metastases.
bEndometrial carcinoma was the source of brain metastases in 3 (0.9%) of 348 patients with brain metastases.
c Patients with recurrent endometrial carcinoma following primary surgery.
d Oral poly(ADP)-ribose polymerase (PARP) 1 inhibitor.